UPLC Liquid Chromatograph Mass Spectrometer

UPLC 液相色谱质谱仪

• 批准号: 8640601
• 负责人: Milan N Stojanovic
• 金额: $ 16.02万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-20 至 2015-04-19
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8640601
• 关键词: 10 year old; Academic Medical Centers; Age; Alzheimer' s Disease; Biological Markers; Biological Process; Biomedical Research; Clinical Research; Core Facility; Custom; Diabetes Mellitus; Disease; Faculty; Funding; Grant; Heart failure; Individual; Institutes; Liquid substance; Malignant neoplasm of prostate; Medicine; Organic Chemistry; Organic Synthesis; Pulmonary Emphysema; Research; Research Personnel; Schizophrenia; Services; Therapeutic; Time; Translational Research; United States National Institutes of Health; age related; beneficiary; chronic pain; drug discovery; experience; instrument; liquid chromatography mass spectrometry; malignant breast neoplasm; mass spectrometer; small molecule

DESCRIPTION (provided by applicant): We request funds to purchase a Shimadzu LCMS-2020 with UFLC XR for a collaborative core facility (The Organic Chemistry Core Center or OCCC) at the Columbia University Medical Center (CUMC). The Organic Chemistry Core Center, including its LC/MS facility, is the only entity offering custom organic synthesis, drug discovery, and instrumental analysis services in support of NIH-funded biomedical research at the CUMC. The instrument will replace a 10-year-old 2010A Shimadzu liquid chromatograph mass spectrometer, which has been experiencing frequent age-related and age-appropriate difficulties. Lack of timely upgrade to a new instrument endangers progress of a large number of grants. The new instrument will enable the continuing support for 25 (a yearly average) individual NIH grants. The primary "hands-on" users of the instrument will be synthetic organic chemists of the Center that make and characterize small molecules directed through a collaborative effort by biomedical researchers at the CUMC. The end beneficiaries of the instrument, that is, the researchers directing the synthetic chemists, span the spectrum from well-established investigators, funded by the NIH for decades, to young faculty, seeking first-time support from the NIH. Their research relies on small molecules characterized by the Center's LC/MS facility to study biological processes associated with various disease states, such as Alzheimer's Disease, schizophrenia, prostate and breast cancer, heart failure, diabetes, chronic pain, and emphysema, among others. The instrument will be co-managed by the Organic Chemistry Core Facility within the Division of Experimental Therapeutics of the Department of Medicine and the Biomarkers Core Facility within the Irving Institute for Clinical and Translational Research at the Columbia University Medical Center (CUMC).

描述（由申请人提供）：我们请求资金购买带有 UFLC XR 的 Shimadzu LCMS-2020，用于哥伦比亚大学医学中心 (CUMC) 的协作核心设施（有机化学核心中心或 OCCC）。有机化学核心中心（包括其 LC/MS 设施）是唯一提供定制有机合成、药物发现和仪器分析服务的实体，以支持 NIH 资助的 CUMC 生物医学研究。该仪器将取代已使用 10 年的 2010A Shimadzu 液相色谱质谱仪，该仪器经常遇到与年龄相关和适合年龄的问题。缺乏及时升级新工具会危及大量赠款的进展。新工具将为 25 项（平均每年）NIH 个人拨款提供持续支持。该仪器的主要“实际”用户将是该中心的合成有机化学家，他们在 CUMC 生物医学研究人员的共同努力下制造和表征小分子。该工具的最终受益者，即指导合成化学家的研究人员，涵盖了从 NIH 资助数十年的成熟研究人员到首次寻求 NIH 支持的年轻教师。他们的研究依靠该中心的 LC/MS 设施表征的小分子来研究与各种疾病状态相关的生物过程，例如阿尔茨海默病、精神分裂症、前列腺癌和乳腺癌、心力衰竭、糖尿病、慢性疼痛和肺气肿等。该仪器将由医学系实验治疗学部的有机化学核心设施和哥伦比亚大学医学中心（CUMC）欧文临床和转化研究所的生物标志物核心设施共同管理。